# Emergent (EBS) — News

EBS · NYSE · Stock

Canonical page: https://www.lighthorse.io/tickers/ebs/news

## Recent headlines

- [FDA expands Altor's Ankitva use to papillary bladder cancer](https://www.ainvest.com/news/fda-expands-altor-ankitva-papillary-bladder-cancer-2610) — AInvest Wire, Oct 14, 2026
  The U.S. Food and Drug Administration (FDA) has received a supplemental biologics license application (sBLA) for nogapendekin alfa inbakicept-pmln (Anktiva), expanding its potential use to treat patients with Bacillus Calmette–Guérin (BCG)–unresponsive non–muscle-invasive bladder cancer (NMIBC)…
- [Monkeypox stocks rose in intraday trading, with EBS up 17.9%, GOVX gaining 24.3% and MRNA rising 6.7%.](https://www.ainvest.com/news/monkeypox-stocks-rose-intraday-trading-ebs-17-9-govx-gaining-24-3-mrna-rising-6-7-2610-64) — AInvest Wire, Oct 5, 2026
  On October 5, 2026, stocks linked to monkeypox vaccine development saw significant intraday gains amid ongoing global health concerns. EBS surged 17.9%, while GOVX climbed 24.3%, and MRNA rose 6.7%. These movements reflect heightened investor interest in biotechnology firms positioned to benefit…
- [Regeneron Pharmaceuticals: Serious TEAEs grade 3+ in 21% of LGSOC patients; TEAEs in 74%; neutropenia, anemia, elevated liver enzymes](https://www.ainvest.com/news/regeneron-pharmaceuticals-teaes-grade-3-21-lgsoc-patients-teaes-74-neutropenia-anemia-elevated-liver-enzymes-2610) — AInvest Wire, Oct 1, 2026
  Regeneron Pharmaceuticals' MEK inhibitor binimetinib, evaluated in the phase III MILO trial for recurrent or persistent low-grade serous ovarian cancer (LGSOC), demonstrated notable toxicity profiles. The trial reported that 74% of patients experienced treatment-emergent adverse events (TEAEs),…
- [Regeneron Pharmaceuticals: TEAEs occurred in 100% of LGSOC patients; cytokine release syndrome in 90%, all grade 1 or 2](https://www.ainvest.com/news/regeneron-pharmaceuticals-teaes-occurred-100-lgsoc-patients-cytokine-release-syndrome-90-grade-1-2-2610) — AInvest Wire, Oct 1, 2026
  Regeneron Pharmaceuticals recently reported preliminary data from a clinical trial involving patients with low-grade serous ovarian cancer (LGSOC). The study indicated that treatment-emergent adverse events (TEAEs) occurred in 100% of participants, with cytokine release syndrome observed in 90% of…
- [Eli Lilly - Treatment-emergent adverse events in 41.8% eBGLySS patients, 39.6% placebo, all mild or moderate](https://www.ainvest.com/news/eli-lilly-treatment-emergent-adverse-events-41-8-ebglyss-patients-39-6-placebo-mild-moderate-2609) — AInvest Wire, Sep 30, 2026

## Similar Stocks

- [JNJ](https://www.lighthorse.io/tickers/jnj) — Johnson & Johnson Common Stock

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).